| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| EBITDA | 0 | -0 | 2 | 2 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | -0 | -0 | -0 | -0 | 0 | -0 | -1 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | 0 | -0 | -1 | -0 |
| Operating Profit % | -86 % | 0 % | -425 % | 0 % | 0 % | 0 % | 0 % | 0 % | 0 % | 0 % | -13 % | -1,900 % | 0 % | 0 % | 0 % | -56 % | -233 % | 0 % | 0 % | 0 % | -120 % | -240 % | -200 % | -520 % | -820 % | -133 % | -113 % | -675 % | -280 % |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -3 | -3 | -1 | -1 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -1 | -2 | -1 | -2 | -0 | -0 | -0 | -0 | 0 | -0 | -0 | -1 | -0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | -3 | -3 | -1 | -1 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -1 | -2 | -1 | -2 | -0 | -0 | -0 | -0 | 0 | -0 | -0 | -1 | -0 |
| EPS in ₹ | 0.00 | -0.35 | -0.12 | -0.10 | -0.37 | -0.36 | -0.35 | -0.37 | -0.35 | -0.35 | -0.33 | -0.34 | -0.34 | -0.34 | -0.35 | -0.34 | -0.18 | -0.23 | -0.18 | -0.19 | -0.02 | -0.02 | -0.02 | -0.04 | 0.03 | -0.01 | -0.01 | -0.09 | -0.06 |
Transgene Biotek
Transgene Biotek
4.02
-0.16
(-3.83%)
Key Fundamentals
Market Cap
30.49 Cr
EPS
-0.09
PE Ratio
-24.59
Dividend Yield
0.00 %
Industry
Healthcare Services 52 Week High
8.00
52 Week Low
3.22
PB Ratio
3.16
Debt to Equity
1.23
Sector
Healthcare Service Provider Actual
Company News
View All News
Transgene Biotek Ltd received notification that Babaji Nethralayya Pvt Ltd has filed a legal case at the NCLT Hyderabad bench over an unpaid loan amount of Rs 6,82,05,834 along with interest and other charges. The matter was heard on October 16, 2025, and has been adjourned to December 16, 2025. The company stated it is making efforts to resolve the matter amicably.
Transgene Biotek Limited's Board approved quarterly financial results showing a net loss of Rs 43.37 lakhs for the quarter ended June 30, 2025, compared to a profit of Rs 19.94 lakhs in the same period last year. Revenue from operations declined to Rs 4.95 lakhs from Rs 4.92 lakhs year-over-year. The company's total expenses increased to Rs 48.32 lakhs, with finance costs rising significantly to Rs 24.55 lakhs from Rs 1.73 lakhs in the previous year. The Board extended the AGM date for financial year 2024-25 and appointed M/s. Manisha Dubey & Associates as Internal Auditors for 2025-26, and M/s. Geeta Serwani & Associates as Secretarial Auditors for a five-year term from April 2025 to March 2030, subject to shareholder approval. The company continues to face challenges due to ongoing SEBI adjudication proceedings, with the next SAT hearing scheduled for September 8, 2025.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
3,091.10 | #1 25,895.85 | 49.89 | #1 2,554.80 | 11.28 | #1 492 | 24.30 | 44.84 | |
1,009.05 | 10,365.46 | 68.07 | 699.70 | 23.06 | 144 | 22.54 | 46.94 | |
1,944.30 | 10,071.90 | 66.10 | 1,346.30 | 10.64 | 146 | 18.90 | 42.43 | |
1,350.00 | 7,154.25 | 55.73 | 702.20 | 20.80 | 91 | 81.06 | 64.57 | |
794.70 | 2,577.90 | 32.23 | 742.70 | 16.70 | 78 | 14.53 | 45.66 | |
316.85 | 1,650.18 | 51.54 | 255.90 | 15.11 | 31 | 19.48 | 66.85 | |
1,328.25 | 1,137.40 | 23.19 | 111.60 | 28.72 | 48 | 11.50 | 35.58 | |
304.00 | 967.04 | #1 -6.43 | 1,170.80 | -18.47 | -134 | -35.12 | 44.49 | |
361.80 | 707.10 | 25.33 | 147.80 | #1 134.60 | 19 | #1 444.44 | 66.60 | |
145.10 | 99.80 | 66.94 | 41.80 | 13.28 | 2 | 0.00 | 25.38 |
Growth Rate
Revenue Growth
100.00 %
Net Income Growth
-88.33 %
Cash Flow Change
-
ROE
-88.42 %
ROCE
-90.95 %
EBITDA Margin (Avg.)
-72.68 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 344 | 313 | 198 | 187 | 177 | 167 | 157 | 147 | 142 | 142 | 144 |
| Fixed Assets | 163 | 141 | 61 | 51 | 41 | 31 | 21 | 11 | 6 | 6 | 10 |
| Current Assets | 18 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Capital Work in Progress | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 180 | 172 | 135 | 134 | 134 | 134 | 134 | 134 | 134 | 134 | 0 |
| Total Liabilities | 344 | 313 | 198 | 187 | 177 | 167 | 157 | 147 | 142 | 142 | 144 |
| Current Liabilities | 25 | 11 | 12 | 14 | 13 | 14 | 14 | 9 | 11 | 11 | 13 |
| Non Current Liabilities | 127 | 127 | 128 | 120 | 120 | 120 | 121 | 121 | 121 | 121 | 121 |
| Total Equity | 191 | 174 | 59 | 52 | 44 | 33 | 22 | 17 | 11 | 11 | 10 |
| Reserve & Surplus | 116 | 99 | -17 | -23 | -32 | -43 | -54 | -58 | -64 | -65 | -66 |
| Share Capital | 76 | 76 | 76 | 76 | 76 | 76 | 76 | 76 | 76 | 76 | 76 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 |
| Investing Activities | -5 | -7 | 0 | 3 | 2 | 0 | 0 | -0 | 0 | 0 |
| Operating Activities | 4 | 7 | 0 | -1 | -2 | 0 | 0 | 0 | 0 | 0 |
| Financing Activities | 1 | 0 | 0 | -2 | 0 | -0 | 0 | 0 | 0 | 0 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 23.64 % | 23.64 % | 23.64 % | 23.64 % | 23.64 % | 23.64 % | 23.64 % | 23.64 % | 23.64 % | 23.64 % | 23.64 % | 23.64 % | 23.64 % | 23.64 % | 23.64 % | 23.64 % | 23.64 % | 23.64 % | 23.64 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| DIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 70.82 % | 71.21 % | 71.71 % | 71.48 % | 71.67 % | 71.68 % | 71.67 % | 71.64 % | 71.22 % | 71.60 % | 71.73 % | 70.10 % | 71.45 % | 71.75 % | 71.74 % | 71.87 % | 71.88 % | 71.89 % | 71.85 % |
| Others | 5.54 % | 5.15 % | 4.65 % | 4.88 % | 4.70 % | 4.69 % | 4.70 % | 4.72 % | 5.14 % | 4.77 % | 4.63 % | 6.26 % | 4.92 % | 4.61 % | 4.62 % | 4.50 % | 4.48 % | 4.48 % | 4.51 % |
| No of Share Holders | 10,337 | 10,769 | 10,793 | 11,130 | 11,317 | 11,331 | 11,303 | 11,432 | 11,371 | 11,342 | 11,360 | 12,220 | 12,426 | 12,766 | 12,963 | 13,307 | 13,583 | 13,475 | 13,461 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 30 Dec 2023 |  Annual General Meeting | NA | 30 Dec 2023 | 6.21 | 9.87 |
| 12 Nov 2024 |  Quarterly Result Announcement | NA | 12 Nov 2024 | 7.07 | 6.80 |
| 05 Dec 2024 | Annual General Meeting | NA | 05 Dec 2024 | 6.80 | 6.85 |
| 24 Jan 2025 | Quarterly Result Announcement | NA | 24 Jan 2025 | 4.52 | 4.71 |
| 07 May 2025 | Quarterly Result Announcement | NA | 07 May 2025 | 3.89 | 3.50 |
| 07 Aug 2025 | Quarterly Result Announcement | NA | 07 Aug 2025 | 4.68 | 4.78 |
Announcements
Declaration Under Clause 36 Of Listing Agreement With BSE - Intimation About The Filing At NCLT (Hyderabad) Bench By M/S BABAJI NETHRALAYYA PRIVATE LTD
Oct 17, 2025
Oct 17, 2025Compliance-57 (4) : Prior intimation to the beginning of the quarterOct 12, 2025
Oct 12, 2025Compliance-57 (5) : intimation after the end of quarterOct 12, 2025
Oct 12, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 12, 2025
Oct 12, 2025Compliance CertificateOct 11, 2025
Oct 11, 2025Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AOct 11, 2025
Oct 11, 2025Statement Of Deviation & VariationOct 11, 2025
Oct 11, 2025Closure of Trading WindowSep 24, 2025
Sep 24, 2025Intimation Extension Of Time For Holding Annual General Meeting Of The Company For The Financial Year Ended On March 31 2025.Sep 08, 2025
Sep 08, 2025Subject: Intimation About The Initiation Of Insolvency Process.
This Is To Inform About The Receipt Of Intimation Today From M/S Babaji Nethralayya Private Limited Initiating An Action Under Section 7 Of The Insolvency And Bankruptcy Code 2016 Read WitSep 01, 2025
Sep 01, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 13, 2025
Aug 13, 2025The Board Considered And Approved The Unaudited Financial Results (Standalone & Consolidated) Of The Company For The Quarter Ended 30Th June 2025.Aug 07, 2025
Aug 07, 2025Board Meeting Outcome for Outcome Of The Board MeetingAug 07, 2025
Aug 07, 2025Board Meeting Intimation for This Is To Inform You That A Meeting Of Board Of Directors Will Be Held On Thursday 07Th August 2025 In Order To Transact Following Businesses.Jul 30, 2025
Jul 30, 2025Compliance-57 (5) : intimation after the end of quarterJul 25, 2025
Jul 25, 2025Statement Of Deviation Or Variation -30Th June 2025Jul 25, 2025
Jul 25, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 20, 2025
Jul 20, 2025Closure of Trading WindowJun 26, 2025
Jun 26, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2025
May 30, 2025Integrated Filing (Financial)May 22, 2025
May 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 12, 2025
May 12, 2025Outcome Of Board Meeting And Submission Of Audited Financial Results For The Fourth Quarter And Financial Year Ended March 31 2025May 07, 2025
May 07, 2025Board Meeting Outcome for Outcome Of Board Meeting And Submission Of Audited Financial Results For The Fourth Quarter And Financial Year Ended March 31 2025May 07, 2025
May 07, 2025Board Meeting Intimation for Intimation Of The Board Meeting Of The Company.
This Is To Inform You That A Meeting Of Board Of Directors Of The Company Will Be Held On Wednesday 07Th May 2025.Apr 26, 2025
Apr 26, 2025Compliance-57 (5) : intimation after the end of quarterApr 26, 2025
Apr 26, 2025We Are Enclosing Hereto The Compliance Certificate As Per Clause 40(9) In The Prescribed Format For The Quarter Ended 31St March 2025Apr 24, 2025
Apr 24, 2025Statement Of Deviation & VariationApr 19, 2025
Apr 19, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 19, 2025
Apr 19, 2025Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 19, 2025
Apr 19, 2025Compliance Certificate Pursuant To Regulation 7(3) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015.Apr 19, 2025
Apr 19, 2025Closure of Trading WindowMar 29, 2025
Mar 29, 2025Integrated Filing (Financial)Feb 14, 2025
Feb 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 12, 2025
Feb 12, 2025The Board Has Considered And Approved The Unaudited Consolidated & Standalone Financial Results Of The Company For The Quarter Ended 31.12.2024 In Accordance With The Indian Accounting Standards (IND-Jan 24, 2025
Jan 24, 2025Board Meeting Outcome for Outcome Of Board Meeting - Scrip Code 526139Jan 24, 2025
Jan 24, 2025Statement Of Deviation & VariationJan 20, 2025
Jan 20, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 20, 2025
Jan 20, 2025Board Meeting Intimation for Intimation Of The Board Meeting To Be Held On Friday 24"January 2025Jan 16, 2025
Jan 16, 2025Clarification On The Adjudication Order Received From The Enforcement Directorate Southern Regional Office.Jan 13, 2025
Jan 13, 2025Closure of Trading WindowDec 31, 2024
Dec 31, 2024Receipt Of Order From The Enforcement Directorate Southern Regional Office.Dec 31, 2024
Dec 31, 2024Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportDec 06, 2024
Dec 06, 2024Shareholder Meeting / Postal Ballot-Outcome of AGMDec 05, 2024
Dec 05, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 15, 2024
Nov 15, 2024Revised ResultsNov 13, 2024
Nov 13, 2024Reg. 34 (1) Annual Report.Nov 12, 2024
Nov 12, 2024Intimation Of Book Closure And Cut -Off Date For The 34Th Annual General Meeting Of Transgene Biotek Limited.Register Of Members And The Share Transfer Books Of The Company Will Remain Closed From Friday The 29Th November 2024 To Thursday The 05Th December, 2024 (Both Days Inclusive) For The Purpose Of 34Th Annual General Meeting Which Is Scheduled To Be Held On Thursday The 05Th December 2024 At IST Through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM') At 10.00 A.M. (IST).Nov 12, 2024
Nov 12, 2024Outcome Of Board Meeting.This Has Reference To Our Letter Dated 03Rd November 2024.At The Meeting Of The Board Of Directors Of The Company Held On Tuesday 12Th November 2024, The Following Decisions Were Taken:1. Un- Audited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended 30.09.2024. (Attached).2.Limited Review Report (Standalone And Consolidated) For The Quarter And Half Year Ended 30.09.2024. (Attached).Nov 12, 2024
Nov 12, 2024Board Meeting Outcome for Outcome Of Board Meeting.Nov 12, 2024
Nov 12, 2024Board Meeting Intimation for Intimation Of The Board Meeting To Be Held On Tuesday, 12Th November, 2024 At 11:00 AmNov 04, 2024
Nov 04, 2024Technical Indicators
RSI(14)
Neutral 50.44
ATR(14)
Less Volatile 0.34
STOCH(9,6)
Neutral 71.29
STOCH RSI(14)
Neutral 23.15
MACD(12,26)
Bearish 0.00
ADX(14)
Weak Trend 15.01
UO(9)
Bearish 71.89
ROC(12)
Uptrend And Accelerating 0.97
WillR(14)
Neutral -22.34
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
